Which is Better to Treat | The Diseased SVG or the Native CTO?

Saturday, March 8, 2025

9:22 AM – 9:30 AM ET

Speaker(s)

Lorenzo Azzalini, MD, PhD, MSc

Interventional Cardiologist
University of Washington
Seattle, Washington, United States

Disclosure(s): Abbott Vascular: Consulting Fees (e.g., advisory boards) (Ongoing); Abiomed: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); GE Healthcare: Consulting Fees (e.g., advisory boards) (Terminated, December 11, 2024); HeartFlow: Consulting Fees (e.g., advisory boards) (Ongoing); Reflow Medical: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-privately held company (Ongoing); Shockwave Medical, Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Teleflex: Consulting Fees (e.g., advisory boards) (Ongoing)

Disclosure(s):

Lorenzo Azzalini, MD, PhD, MSc: Abbott Vascular: Consulting Fees (e.g., advisory boards) (Ongoing); Abiomed: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); GE Healthcare: Consulting Fees (e.g., advisory boards) (Terminated, December 11, 2024); HeartFlow: Consulting Fees (e.g., advisory boards) (Ongoing); Reflow Medical: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-privately held company (Ongoing); Shockwave Medical, Inc: Consulting Fees (e.g., advisory boards) (Ongoing); Teleflex: Consulting Fees (e.g., advisory boards) (Ongoing)